{"id":529273,"date":"2021-02-08T16:04:01","date_gmt":"2021-02-08T16:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=529273"},"modified":"2021-02-08T16:04:01","modified_gmt":"2021-02-08T16:04:01","slug":"hypertrophic-cardiomyopathy-hcm-market-size-share-growth-trends-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hypertrophic-cardiomyopathy-hcm-market-size-share-growth-trends-leading-companies-emerging-drugs-and-epidemiology-forecast_529273.html","title":{"rendered":"Hypertrophic Cardiomyopathy (HCM) Market Size, Share, Growth, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"
\"Hypertrophic<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Hypertrophic Cardiomyopathy (HCM) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM), historical and forecasted epidemiology as well as the Hypertrophic Cardiomyopathy (HCM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

Hypertrophic cardiomyopathy (HCM)<\/strong> is the most common genetic heart disease and an important cause of sudden death and heart failure symptoms. The current prevalence for Hypertrophic Cardiomyopathy (HCM)<\/strong> is based on echocardiographic population studies in which a substantial proportion of affected subjects have not come to clinical recognition. In addition, most patients with HCM<\/strong> never develop (or recognize) cardiovascular symptoms, experience an adverse disease-related event, or are identified with another clinical marker (e.g., abnormal electrocardiogram and family history) which could lead to clinical Recognition.<\/p>\n

hypertrophic cardiomyopathy (HCM)<\/strong> can affect people of any age. It affects men and women equally but sometimes the prevalence of HCM is evaluated more in men as compared to women. It is a common cause of sudden cardiac arrest in young people, including young athletes.<\/p>\n

Get FREE sample copy at: <\/strong>
https:\/\/www.delveinsight.com\/sample-request\/hypertrophic-cardiomyopathy-market<\/a><\/strong><\/p>\n

The Hypertrophic Cardiomyopathy market<\/strong> report also covers emerging drugs, current treatment practices, Hypertrophic Cardiomyopathy (HCM) market share of the individual therapies, current and forecasted Hypertrophic Cardiomyopathy (HCM) Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Hypertrophic Cardiomyopathy treatment practice<\/strong>\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. <\/p>\n

 <\/p>\n

\"Hypertrophic<\/p>\n

 <\/p>\n

Hypertrophic Cardiomyopathy (HCM) Market Key Facts
<\/strong>As per the US National Library of medicine 2019, the familial form of HOCM<\/strong> is an autosomal dominant genetically transmitted disorder. It is the most common genetically transmitted cardiomyopathy, which can also occur in individuals without family history secondary to de novo mutations. Familial hypertrophic cardiomyopathy affects about 1 in 500 people worldwide. It is the most common genetic heart disease in the United States.<\/p>\n

As per Husser et al. (2018), in Germany Hypertrophic Cardiomyopathy (HCM) prevalence<\/strong> increased gradually with age from 7.4\/100,000 persons in 0–9 years old to 298.7\/100,000 persons in patients >80 years. In all age categories, men had a numerically higher prevalence than women.<\/p>\n

Various studies show a higher prevalence of Hypertrophic Cardiomyopathy (HCM)<\/strong> in males as compared to females<\/p>\n

As per the article by Marian et al. (2017), the prevalence of Hypertrophic Cardiomyopathy <\/strong>has been estimated at 0.16% to 0.29% in the general adult population.<\/p>\n

Key Benefits of Hypertrophic Cardiomyopathy (HCM) Market Report<\/strong><\/p>\n